Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PRNP | P04156 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633853 | 0.84 | HSD17B10 (0.52) | CYP1A2RAB9ANPC1POLBHSP90AA1 | |
| SCHEMBL7153877 | 0.81 | L3MBTL1 (0.60) | POLBALDH1A1HSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL8870482 | 0.80 | HSD17B10 (0.62) | RAB9ANPC1POLBALDH1A1HSD17B10 | |
| SCHEMBL1514431 | 0.79 | TYMS (0.62) | CYP1A2POLBALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL2407025 | 0.79 | CYP1A2 (0.61) | CYP1A2RAB9ANPC1POLBHSP90AA1 | |
| SCHEMBL28728287 | 0.79 | CYP1A2 (0.65) | CYP1A2RAB9ANPC1POLBHSP90AA1 | |
| SCHEMBL18301097 | 0.78 | ALDH1A1 (0.55) | CYP1A2POLBALDH1A1HSD17B10KDM4E | |
| SCHEMBL28473859 | 0.78 | ALDH1A1 (0.55) | CYP1A2RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL2027600 | 0.77 | LMNA (0.59) | CYP1A2RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL4853402 | 0.77 | CYP1A2 (0.62) | CYP1A2RAB9ANPC1POLBHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685121-B1 | ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-7375130-B2 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20070078178-A1 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | MERCK PATENT GMBH (DE) | 2007-04-05 | — | — | US | disclosed |
| EP-1685121-A1 | ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005054225-A1 | ANTIDIABETIC COMPOUNDS COMPRISING BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078178-A1 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | GPR119, INSR, GLP1R | CYP1A2 499/4885RAB9A 3593/4885NPC1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.